Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
37 Results for "
MDM2-p53 interaction
" in MedChemExpress (MCE) Product Catalog:
Products (37)
37 Results for "MDM2-p53 interaction" in MCE Product Catalog:
Cat. No.: HY-16634
CAS No.: 1303609-30-4
MI-888 (TFA) is an orally active MDM2-p53 interaction inhibitor with a Ki of 0.44 nM. MI-888 (TFA) can achieve rapid, complete, and sustained tumor regression in a xenograft mouse model of cancer .
Cat. No.: HY-12941
CAS No.: 1623432-51-8
AM-7209 is a potent and selective MDM2-p53 interaction inhibitor with a Kd of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC50 of 1.6 nM. AM-7209 shows antitumor activities .
Cat. No.: HY-124070
CAS No.: 1254366-73-8
ISA 27 is a small-molecule MDM2-p53 protein-protein interaction inhibitor. ISA 27 inhibits MDM2-mediated p53 ubiquitination and degradation. ISA 27 is promising for research of p53-mutant solid tumors (e.g., thyroid, breast cancer) .
Cat. No.: HY-161039
CAS No.: 1818291-95-0
MDM2-p53-IN-18 (Compd A-7b) is a MDM2-p53 interaction inhibitor .
Cat. No.: HY-161041
CAS No.: 2095120-09-3
MDM2-p53-IN-20 (Compd B-11j) is a synthetic MDM2-p53 interaction inhibitor that play an important role in cancer .
Cat. No.: HY-161040
CAS No.: 1818292-01-1
MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the MDM2-p53 interaction with anticancer activity .
Cat. No.: HY-P10286
CAS No.: 186180-20-1
Cat. No.: HY-W704348
Cat. No.: HY-122038
CAS No.: 849723-20-2
NU-8165 is an inhibitor of the MDM2-p53 protein-protein interaction with anti-tumor activity. Optimization of NU-8165 was guided by MDM2 NMR titrations, which indicated key binding interaction regions. NU-8165 activated MDM2 and p21 transcription in cell-based assays and showed modest selectivity for wild-type p53 cell lines .
Cat. No.: HY-133754
CAS No.: 1410737-39-1
Research Areas:
MI-1063 is an inhibitor for MDM-2, that blocks the MDM2-p53 interaction, and activates the tumor suppressor function of p53. MI-1063 inhibits the growth of cancer cell RS4-11 and MV4-11 with IC50 of 179 nM and 93 nM. MI-1063 can be used as target protein ligand in synthesis of PROTAC degrader MD-265 (HY-169327) .
Cat. No.: HY-18986S
Synonyms: MI-77301-d10
Cat. No.: HY-163083
CAS No.: 3035577-19-3
JN122, a spiroindoline-containing molecule, is a MDM2 inhibitor. JN122 Inhibits MDM2/p53 protein–protein interaction and exerts robust in vivo antitumor efficacy. JN122 has antiproliferative activity in HCT-116 cells and HEK-293 cells with IC50 values of 39.6 nM and 4.28μM, respectively. JN122 can promote activation of p53 and its target genes, inhibited cell cycle progression, and induced cell apoptosis .
Cat. No.: HY-125858B
CAS No.: 1410738-90-7
Research Areas:
(S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
Cat. No.: HY-107466
CAS No.: 1067654-70-9
WK298 is a potent inhibitor of the MDM2/MDMX-p53 interaction with good anti-tumor activity. WK298 can fully activate the p53 pathway by inhibiting the binding of MDM2 and MDMX to p53. The development of WK298 benefited from a deep understanding of the key elements of the p53-MDM2/MDMX interaction structure .
Cat. No.: HY-10029R
CAS No.: 675576-98-4
Synonyms: Rebemadlin (Standard)
Research Areas:
Nutlin-3a (Standard) is the analytical standard of Nutlin-3a (HY-10029). This product is intended for research and analytical applications. Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas .
Cat. No.: HY-L109
826 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.
However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.
With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 826 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
